3 reasons we now favor the healthcare sector

The healthcare sector has been upgraded to a preferred status following three years of underperformance driven by policy uncertainty and earnings pressure. Analysts report a significant turnaround fueled by resolved drug-pricing disputes, stabilized earnings guidance, and a surge in merger and acquisition activity. This shift suggests the sector is well-positioned for valuation recovery and growth heading into 2026 as regulatory headwinds dissipate.

The healthcare sector's recent upgrade follows a period of valuation compression caused by policy uncertainty, specifically the Trump administration’s "most favored nation" drug pricing initiative. This proposal aimed to align U.S. drug prices with lower international rates, which threatened the margins of pharmaceutical and life sciences companies. However, sentiment shifted in late September when Pfizer reached a landmark agreement with the administration, setting a precedent that resolved major policy overhangs. Consequently, healthcare has become the best-performing sector quarter-to-date, rising 7% compared to a 1% gain for the S&P 500.

Third-quarter earnings results have provided much-needed clarity, indicating that pressured industries like life sciences and managed care are beginning to bottom out. Healthcare companies exceeded Q3 estimates by 13%, significantly higher than the broad market’s 7% beat rate and the highest for the sector in at least two years. This stabilization in earnings and guidance allows managed care firms to maintain their 2026 outlooks while life sciences end markets show signs of recovery. Historically, healthcare has outpaced the broader market in earnings growth over 30 years, and current data suggests a return to this trend after a five-year period of underperformance.

Accelerating M&A activity is also revitalizing the sector, particularly as large-cap pharmaceutical companies face an estimated $150 billion in revenue losses due to patent expirations through the end of the decade. Since Labor Day, biotechnology has emerged as the busiest sector for deal-making, averaging one transaction per week and putting 2025 on track for its strongest M&A performance since 2021. This surge in activity is particularly impactful for small-cap biotech firms, which serve as primary acquisition targets for larger companies looking to replenish their product pipelines. With 35 biotech deals recorded year-to-date as of late October, the sector leads all other categories in corporate consolidation.